Osilodrostat + Placebo
ApprovedRecruiting 0 watching 0 views this week๐ฅ Hot
82
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Hypertension
Conditions
Hypertension, Hypercortisolemia, Cushing Syndrome
Trial Timeline
Aug 1, 2026 โ Jul 1, 2028
NCT ID
NCT07247162About Osilodrostat + Placebo
Osilodrostat + Placebo is a approved stage product being developed by Recordati for Hypertension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07247162. Target conditions include Hypertension, Hypercortisolemia, Cushing Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07247162 | Approved | Recruiting |
Competing Products
20 competing products in Hypertension